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Abstract
Background: Apolipoprotein E allele ε4 (apoE4) is a strong risk factor for developing Alzheimer's
disease (AD). Secreted apoE has a critical function in redistributing lipids among central nervous
system cells to maintain normal lipid homeostasis. In addition, previous reports have shown that
apoE4 is cleaved by a protease in neurons to generate apoE4(1–272) fragment, which is associated
with neurofibrillary tanglelike structures and mitochondria, causing mitochondrial dysfunction.
However, it still remains unclear how the apoE fragment associates with mitochondria and induces
mitochondrial dysfunction.
Results: To clarify the molecular mechanism, we carried out experiments to identify intracellular
apoE-binding molecules and their functions in modulating mitochondria function. Here, we found
that apoE4 binds to ubiquinol cytochrome c reductase core protein 2 (UQCRC2) and cytochrome
C1, both of which are components of mitochondrial respiratory complex III, and cytochrome c
oxidase subunit 4 isoform 1 (COX IV 1), which is a component of complex IV, in Neuro-2a cells.
Interestingly, these proteins associated with apoE4(1–272) more strongly than intact apoE4(1–
299). Further analysis showed that in Neuro-2a cells expressing apoE4(1–272), the enzymatic
activities of mitochondrial respiratory complexes III and IV were significantly lower than those in
Neuro-2a cells expressing apoE4(1–299).
Conclusion: ApoE4(1–272) fragment expressed in Neuro2a cells is associated with mitochondrial
proteins, UQCRC2 and cytochrome C1, which are component of respiratory complex III, and with
COX IV 1, which is a member of complex IV. Overexpression of apoE4(1–272) fragment impairs
activities of complex III and IV. These results suggest that the C-terminal-truncated fragment of
apoE4 binds to mitochondrial complexes and affects their activities, and thereby leading to
neurodegeneration.
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Background
It has been shown that the prevalence of Alzheimer's dis-
ease (AD) is associated with the polymorphisms of genes
related to cholesterol metabolism, including apolipoprotein
E (apoE) [1-3], ATP-binding cassette transporter A1 (ABCA1)
[4], and CYP46, the gene encoding cholesterol 24-hydrox-
ylase [5,6]. Human apoE, a 34-kDa protein with 299
amino acids, has three major isoforms, apoE2, apoE3, and
apoE4 [7-9]. It is well known that the possession of apoE4
allele is a major risk factor for Alzheimer's disease (AD)
[1-3]. The apoE4 allele, which is found in 40–65% of
cases of sporadic and familial AD, increases the occur-
rence and lowers the age of onset of the disease [3,10]. In
the central nervous system, apoE is one of the major lipid
acceptors [11,12] and interacts with ABCA1 [13] to
remove cholesterol from cells and generate high-density
lipoprotein (HDL) particles [14] in an apoE-isoform-spe-
cific manner [15-18]. Because apoE-HDL is the major cho-
lesterol supplier in the brain and the supply of HDL-
cholesterol is essential for synaptogenesis and neurite out-
growth in neurons [19,20], the apoE-isoform-dependent
difference in HDL generation may result in the apoE-iso-
form-dependent difference in the maintenance of synap-
tic plasticity and the recovery of neurons from neuronal
damage found in AD brains.
In addition to the role of apoE in modulating extracellular
lipid transport, the isoform-dependent intracellular func-
tions of apoE have also been reported. A previous report
has shown that apoE3 recycling is associated with con-
comitant cholesterol efflux and thereby contributes to the
formation of apoE-containing HDL, whereas apoE4 recy-
cling is impaired and apoE4 accumulates within endo-
somal compartments, inducing an impaired cholesterol
efflux [21], which may lead to the accumulation of cellu-
lar cholesterol and enhanced amyloid β-protein (Aβ) gen-
eration [22]. Another effect of reduced recycling of apoE4
is due to the tight binding of apoE4 to LDLR and LRP1 in
the endosomal compartment [21], which in turn affects
the interaction of the amyloid precursor protein (APP)
and LRP1 that is crucial for the generation of Aβ [23,24].
Other lines of evidence have shown that apoE is cleaved
by a protease to generate C-terminal-truncated fragments
of apoE (residues 1–272) (apoE4(1–272)) in cultured
neuronal cells, and the apoE(1–272) fragment is found in
the brains of AD patients and transgenic mice expressing
human apoE [25,26]. This proteolytic cleavage occurs in
neurons, but not in astrocytes, and C-terminal-truncated
fragments of apoE accumulated in an age-dependent
manner in the brains of apoE4 mice and, to a significantly
lesser extent, apoE3 mice [26]. These fragments, particu-
larly apoE4(1–272), cause AD-like neurodegeneration
and memory deficits in transgenic mice expressing
apoE4(1–272) [27]. These lines of evidence suggest that
the intraneuronal proteolytic processing of apoE could
enhance the neuropathology and promote neurodegener-
ation in AD brains. It has been shown that the presence of
a lipid-binding region of apoE (residues 244–272) is crit-
ical for apoE fragments to exert neurotoxicity in vivo [27].
Previous studies have shown that residues 267–299 are
responsible for the tetramerization of apoE in solution,
and the truncation of residues 273–299 in apoE4 gives
rise to the monomeric form [28], and that these hydro-
phobic residues appear to be responsible for the neurotox-
icity caused by the C-terminal-truncated apoE4 fragments
[29]. In addition to the strong neurotoxicity caused by the
apoE4(1–272) fragment, it has been shown that the
apoE4(1–272) fragment accumulates in filamentous neu-
rofibrillary tanglelike structures with phosphorylated tau
in the cytosol or mitochondria, inducing mitochondrial
dysfunction [25-27,29]. However, it still remains unclear
how the apoE fragments are transported to the filamen-
tous cytoplasmic structures or to mitochondria, and how
they associate with mitochondria and induce mitochon-
drial dysfunction. To address these questions, we per-
formed experiments to identify the proteins that associate
with apoE4(1–272) or intact apoE4(1–299), and deter-
mine their functions. We identified three apoE4-binding
proteins, all of which are components of mitochondria.
We found that these proteins preferentially bind to
apoE4(1–272) than to apoE4(1–299) and that the overex-
pression of apoE4(1–272) fragment decreases the enzy-
matic activities of mitochondrial respiratory complexes III
and IV in cultured cells.
Results
Identification of apoE4-associated proteins
To identify molecules that specifically bind to apoE4, var-
ious fractions obtained from mouse brain were loaded
onto a FLAG-apoE4(1–272) or FLAG-apoE4(1–299)
affinity column. The proteins bound to these columns
were eluted with an excess amount of FLAG peptide and
the extracts were subjected to SDS-PAGE and silver stain-
ing. When each mouse brain fraction was loaded onto a
FLAG-apoE4(1–272) or FLAG-apoE4(1–299) affinity col-
umn and eluted samples were subjected to SDS-PAGE,
many protein bands were detected as candidate apoE4-
associated proteins (Fig. 1). These bands were detected
only when the mouse brain fractions and FLAG-apoE4
recombinant proteins coexisted.
To identify these proteins, the protein bands were sub-
jected to LC-MS/MS analysis. As a result, we identified six-
teen apoE4-associated proteins, which are shown in Table
1. These candidate proteins include the ATP synthase pro-
tein α and β subunits, which were previously reported
[30]. Interestingly, ten among the candidate proteins are
shown to be associated with mitochondria.Molecular Neurodegeneration 2009, 4:35 http://www.molecularneurodegeneration.com/content/4/1/35
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Association of identified proteins with apoE4 in cultured 
cells
Next, we examined whether these proteins really associate
with apoE in living cells. We cotransfected each candidate
protein and FLAG-apoE4 into Neuro2a cells. Twenty-four
hours following the transfection, the cells were harvested
and treated with Triton X-100 solubilization buffer to
obtain cell lysate as described in Materials and Methods.
We carried out immunoprecipitation using these samples
with an anti-FLAG antibody. The immunoprecipitate was
then subjected to western blotting analysis using antibody
specific for each protein or anti-HA antibody. This is
because, in case we could not find antibodies specific for
some candidate proteins, we could still generate HA-
tagged proteins. Among the proteins identified by LC-MS/
MS analysis, we found that three proteins, ubiquinol cyto-
chrome c reductase core protein 2 (UQCRC2), cyto-
chrome C1, and cytochrome c oxidase subunit 4 isoform
1 (COX IV 1) were associated with apoE4(1–299) and
apoE4(1–272).
To examine whether mouse UQCRC2 is really associated
with apoE proteins in cells, Neuro2a cells were cotrans-
fected with mammalian expression plasmids encoding
FLAG-apoE4(1–272) or FLAG-apoE4(1–299) and plas-
mids encoding mouse UQCRC2. Western blot analysis
showed that the signal representing mouse UQCRC2 was
clearly detected in the immunoprecipitate from the cells
cotransfected with apoE4(1–272), while a very faint sig-
nal for UQCRC2 was detected in that from the cells
cotransfected with apoE4(1–299). ApoE proteins were
similarly immunoprecipitated in both samples (Fig. 2A).
These results suggest that UQCRC2 prefers to associate
with apoE4(1–272) than with apoE4(1–299).
To examine whether human UQCRC2 also associates
with apoE4, we performed an experiment using human
HA-tagged UQCRC2 expression vector. Similar to the
results using mouse UQCRC2-transfected cells, the signals
representing human HA-tagged UQCRC2 were clearly
detected in the immunoprecipitate from the cells cotrans-
fected with apoE4(1–272), while a very faint signal for
HA-UQCRC2 was detected in that from the cells cotrans-
fected with apoE4(1–299). Under these conditions,
apoE4(1–272) and apoE4(1–299) proteins were similarly
immunoprecipitated in both samples (Fig. 2B).
Next, we examined the association of human cytochrome
C1 and apoE proteins using Neuro2a cells cotransfected
with HA-tagged human cytochrome C1 expression vector
and plasmids encoding FLAG-apoE4(1–272) or FLAG-
apoE4(1–299). A strong signal for HA-tagged human
cytochrome C1 was detected in the immunoprecipitate
from the cell samples expressing apoE4(1–272), while a
very faint signal for cytochrome C1 was detected in those
transfected with apoE4(1–299) plasmid. ApoE4(1–272)
and apoE4(1–299) proteins were similarly detected in
both samples (Fig. 2C).
In addition, whether COX IV 1 is associated with apoE
was determined. Human COX IV 1 was immunoprecipi-
tated in the samples from apoE4(1–272)-expressing cells
The proteins coimmunoprecipitated with apoE4 in the mem- brane extracts from mouse brain Figure 1
The proteins coimmunoprecipitated with apoE4 in 
the membrane extracts from mouse brain. Mouse 
brain membrane extracts were applied to the FLAG-
apoE4(1–299) or FLAG-apoE4(1–272)-anti-FLAG M2-agar-
ose affinity resin column and then eluted with the elution 
buffer. The eluant was dialyzed against the dialysis buffer, 
concentrated, and subjected to SDS-PAGE. The gels were 
stained with SilverQuest Silver Staining kit (Invitrogen). The 
protein bands (arrows), which were absent in the brain sam-
ples without apoE4s, and in the apoE4s samples without 
brain, were subjected to LC-MS/MS analysis.
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and a very faint signal for COX IV 1 was detected in the
samples from apoE4(1–299)-expressing cells, whereas
apoE4(1–272) and apoE4(1–299) proteins were similarly
immunoprecipitated in both samples (Fig. 3). Interest-
ingly, these proteins, UQCRC2, cytochrome C1, and COX
IV 1, are associated more strongly with apoE4(1–272)
than with apoE4(1–299). Concerning other proteins, we
carried out similar experiments; however, no association
of these proteins with apoE4(1–272) and apoE4(1–299)
was found in cultured cells (data not shown).
The levels of apoE4 in mitochondrion-rich fraction isolated 
from ApoE4(1–272)- or ApoE4(1–299)-expressing cells
The results indicate that apoE4(1–272) binds to mito-
chondrial proteins; therefore, we next determined
whether the levels of apoE4(1–272) and apoE4(1–299)
are also associated with the mitochondria. We, thus,
determined the levels of apoE4(1–272) and apoE4(1–
299) in mitochondrion-rich fractions isolated from
Neuro2a cells transfected with apoE4(1–272) or
apoE4(1–299). The level of apoE4(1–272) in the pellet, a
mitochondrion-rich fraction, was greater than that of
apoE4(1–299) (Fig. 4). VDAC, a mitochondrion marker,
was recovered in the pellet fraction (Fig. 4).
Effect of apoE4(1–272) overexpression on activities of 
mitochondrial respiratory complexes
It is known that UQCRC2 and cytochrome C1 are subu-
nits of mitochondrial respiratory complex III and COX IV
1 is a subunit of mitochondrial respiratory complex IV. It
Table 1: ApoE-associated proteins identified by LC-MS/MS analysis
Protein Intracellular localization Function
Solute carrier family 25 (mitochondrial carrier, Aralar) 
member 12
Mitochondria Calcium-dependent mitochondrial aspartate and glutamate 
carrier
Ubiquinol cytochrome c reductase core protein 1 Mitochondria Mitochondrial electron transport
* Ubiquinol cytochrome c reductase core protein 2 (UQCRC2) Mitochondria Mitochondrial electron transport
* Cytochrome C1 Mitochondria Mitochondrial electron transport
Cytochrome oxidase subunit II Mitochondria Mitochondrial electron transport
* Cytochrome c oxidase subunit IV isoform 1 (COX IV1) Mitochondria Mitochondrial electron transport
ATP synthase, H+ transporting, mitochondrial F1 complex, 
α subunit, isoform 1
Mitochondria ATP synthesis
ATP synthase, H+ transporting, mitochondrial F1 complex, β 
subunit
Mitochondria ATP synthesis
ATP synthase, H+ transporting, mitochondrial F1 complex, δ 
subunit
Mitochondria ATP synthesis
Methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent)- 1 like
Mitochondria Folic acid and derivative biosynthetic process
Syntaxin binding protein 1 Cytoplasm Modulates exocytosis of dense-core granules
Nonmuscle myosin heavy chain Cytoplasm Actin filament-based movement
Tubulin, alpha 1A Cytoplasm Constituent of microtubules
RAB3A, member RAS oncogene family Cytoplasm Involved in exocytosis by regulating a late step in synaptic 
vesicle fusion.
Progesterone receptor membrane component 1 Plasma membrane Receptor for progesterone
Cardiotrophin-like cytokine factor 1 Extracellular space Cell surface receptor linked signal transduction
ApoE4-associated protein bands that were detected with SDS-PAGE were prepared and analyzed as described in the Methods. Asterisks (*) show the 
apoE-binding proteins identified and characterized in this study.Molecular Neurodegeneration 2009, 4:35 http://www.molecularneurodegeneration.com/content/4/1/35
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was reported that apoE4(1–272) induces mitochondrial
dysfunction [25-27,29]. Because these proteins are associ-
ated more strongly with apoE4(1–272) than with
apoE4(1–299), we investigated whether the enzymatic
activities of mitochondrial respiratory complexes III and
IV change, when apoE4(1–272) is overexpressed in cul-
tured cells. Complex III activity was expressed as the dif-
ference in the reduction of cytochrome c with or without
antimycin A and myxothiazol, both of which are complex
III inhibitors. Expectedly, the complex III activity of
apoE4(1–272)-overexpressing Neuro2a cells was lower
than that of apoE4(1–299)-overexpressing cells (Fig. 5A).
Because apoE4(1–272) associates with UQCRC2 and
cytochrome C1, there was a possibility that the decrease in
complex III activity in Neuro2a cells expressing apoE4(1–
272) was due to the interaction between apoE4 and com-
plex III. Complex IV activity was expressed as the differ-
ence in the oxidation of ferrocytochrome C with or
without KCN and Na3N, both of which are complex IV
inhibitors. The complex IV activity of apoE4(1–272)-over-
expressing cells was significantly lower than that of
apoE4(1–299)-overexpressing cells (Fig. 5B). The levels of
the mitochondrial proteins UQCRC2 and cytochrome C1
in apoE4(1–272)- and apoE4(1–299)-overexpressing
cells were similar, as demonstrated by western blot analy-
sis using anti-UQCRC2 and anti-cytochrome C1 antibod-
ies (Fig. 5C).
Effects of overexpression of apoE4(1–272) and apoE4(1–
299) on ATP synthase activity and mitochondrial 
membrane potential
Because apoE4(1–272) decreases the activities of mito-
chondrial complexes III and IV, we next examined
whether the overexpression of apoE4(1–272) also affects
ATP synthase activity and mitochondrial membrane
potential. Unexpectedly, apoE4(1–272) and apoE4(1–
299) showed no effect on ATP synthase activity (Fig. 6A).
We further examined the effect of the overexpression of
ApoE4 interacts with the subunits of mitochondrial respira- tory complex III in Neuro2a cells Figure 2
ApoE4 interacts with the subunits of mitochondrial 
respiratory complex III in Neuro2a cells. Neuro2a cells 
were cotransfected with mammalian expression plasmids 
encoding FLAG-apoE4(1–272) or FLAG-apoE4(1–299) and 
plasmids encoding mouse UQCRC2, human HA-UQCRC2, 
or human HA-cytochrome C1, all of which are candidate 
proteins suggested to be associated with apoE4 (Table 1). 
Twenty-four hours following the transfection, the cells were 
harvested and treated with 500 μl of Triton X-100 solubiliza-
tion buffer to obtain cell lysate. The cell lysate was then incu-
bated with anti-FLAG M2-agarose affinity resin, and the 
protein binding to the affinity column was eluted using FLAG 
peptide, and the eluted protein was then analyzed by western 
blotting with anti-UQCRC2 (mouse UQCRC2) antibody (A), 
anti-HA antibody (human UQCRC2) (B), or anti-HA anti-
body (human cytochrome C1) (C).
IP : anti-FLAG
WB : anti-UQCRC2
WB : anti-apoE
WB : anti-HA
WB : anti-apoE
IP : anti-FLAG
(HA-human UQCRC2)
apoE4
(1-299)
apoE4
(1-272)
mock
apoE4
(1-299)
apoE4
(1-272)
mock
A
B
IP : anti-FLAG
WB : anti-HA
WB : anti-apoE
apoE4
(1-299)
apoE4
(1-272)
mock
C
(HA-human
Cytochrome C1)
ApoE4 interacts with the subunits of mitochondrial respira- tory complex IV in Neuro2a cells Figure 3
ApoE4 interacts with the subunits of mitochondrial 
respiratory complex IV in Neuro2a cells. Neuro2a cells 
were co-transfected with FLAG-apoE4 (1–272 or 1–299) 
plasmids and mammalian expression plasmids encoding the 
candidate apoE4-associated proteins. The cells were treated 
with 500 μl of Triton X-100 solubilization buffer and the cell 
lysate was incubated with anti-FLAG M2-agarose affinity 
resin. The immunoprecipitates were then analyzed by west-
ern blotting with an anti-COX IV 1 antibody (human COX IV 
1).
IP : anti-FLAG
WB:anti-COX IV 1
WB : anti-apoE
(human COX IV 1)
apoE4
(1-299)
apoE4
(1-272)
mockMolecular Neurodegeneration 2009, 4:35 http://www.molecularneurodegeneration.com/content/4/1/35
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apoE4(1–272) and apoE4(1–299) on mitochondrial
membrane potential. Neuro2a cells transfected with these
apoE4 species were stained with JC-1, a fluorescent dye
that has been shown to be a reliable indicator of mito-
chondrial membrane potential changes in intact cells.
After three hours of treatment of Neuro2a cells with 1 μM
valinomycin, a K+ ionophore that disrupts the transmem-
brane electrical gradient, the intensity of red fluorescence
(FL2) markedly decreased, whereas that of green fluores-
cence (FL1) slightly increased, as demonstrated by JC-1
staining (Fig. 6B), indicating the dissipation of mitochon-
drial membrane potential. On the other hand, there were
no significant differences in FL1 and FL2 intensities
among Neuro2a cells transfected with mock, apoE4(1–
272) and apoE4(1–299) (Figs. 6B, C, and 6D), indicating
that the overexpression of apoE4(1–272) and apoE4(1–
299) has no effect on mitochondrial membrane potential.
Discussion
Here, we show the molecules associated with apoE pro-
tein. Among the molecules identified, we show for the
first time that apoE4, particularly C-terminal cleaved
apoE4(1–272), binds to UQCRC2 cytochrome C1 and
COX IV 1. Although apoE(1–272) has been shown to be
translocated to mitochondria, it still remains unclear how
the apoE fragments associate with mitochondria and
induce mitochondrial dysfunction. The present study has
shown that apoE4(1–272) binds to UQCRC2 cytochrome
C1, a component of complex III, and COX IV 1, a compo-
nent of complex IV, and that overexpression of apoE(1–
The level of apoE4(1–272) recovered from the mitochon- drion-rich fraction is greater than that of apoE4(1–299) Figure 4
The level of apoE4(1–272) recovered from the mito-
chondrion-rich fraction is greater than that of 
apoE4(1–299). Neuro2a cells transfected with ApoE4(1–
272) and ApoE4(1–299) plasmids were harvested and 
homogenized with a homogenizing buffer (10 mM Tris-HCl, 
pH 7.4, 1 mM EDTA, 0.25 M sucrose), and the resulting 
homogenate was centrifuged at 1,000 g for 10 min at 4°C. 
The resulting supernatant was further centrifuged at 8,000 g 
for 20 min at 4°C. The resulting precipitate (ppt) was used as 
the mitochondrion-rich fraction. Equal amounts of proteins 
from the ppt and supernatant (sup) fractions were analyzed 
by western blot analysis using the anti-apoE antibody, AB946, 
and the anti-VDAC antibody. VDAC was used as the mito-
chondrion marker.
apoE
VDAC
apoE4(1-272)
apoE4(1-299)
apoE4(1-272)
apoE4(1-299)
ppt sup
ppt sup
Overexpression of apoE4(1–272) results in the decreased  level of complex III and IV activities Figure 5
Overexpression of apoE4(1–272) results in the 
decreased level of complex III and IV activities. Enzy-
matic assays of respiratory chain complexes III (A) and IV (B) 
from Neuro2a cells overexpressing FLAG-apoE4(1–272 or 
1–299) were determined as described in the Methods. The 
mitochondria levels in apoE4(1–272)- and apoE4(1–299)-
overexpressing cells were determined by western blot analy-
sis using the anti-UQCRC2 and the anti-cytochrome C1 anti-
bodies (C). Data are the mean ± SEM of nine independent 
experiments. * P < 0.005, ** P < 0.0005 (t-distribution test).
Complex III Complex IV
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272) fragment in Neuro2a cells results in decreases in the
levels of complex III and complex IV activities compared
with those in cells overexpressing intact apoE4. These
results suggest that the apoE4(1–272) fragment binds to
UQCRC2 cytochrome C1 and COX IV 1, thereby inhibit-
ing complex III and complex IV activities, respectively.
The candidate molecules, which may associate with apoE
to transport apoE to mitochondria, were not identified in
our present analysis (Table 1). This should be addressed
in a future study.
Another finding in the present study is that UQCRC2
cytochrome C1 and COX IV 1 are associated more
strongly with ApoE4(1–272) than with intact apoE4(1–
299) (Figs. 2, 3). There are at least two possible explana-
tions for this result. One explanation is that apoE4(1–
272) is structurally different from apoE4(1–299), result-
ing in the difference in hydrophobicity or binding affinity
to other proteins. It has been shown that the C-terminus
of apoE (residues 253–289) participates in hydrophobic
interactions that stabilize the tetramer [28], and that these
hydrophobic residues are suggested to be responsible for
inducing neurotoxicity caused by the C-terminal-trun-
cated apoE4 [29]. In addition, a recent study has shown
that apoE4 lacking a hydrophobic C-terminal α-helical
segment (residues 273–299) found in brain leads to a less
organized C-terminal structure that is available for inter-
action with cell membranes and other proteins such as Aβ
[31]. Another explanation is that more apoE(1–272) is
translocated to mitochondria than intact apoE(1–299),
because the silver staining shows that the intensities of the
bands representing apoE-associated proteins were not dif-
ferent between the samples containing apoE4(1–272)
and apoE4(1–299) (Fig. 1), whereas the level of apoE4(1–
272) was greater than that of apoE4(1–299) in the mito-
chondrion-rich fraction of Neuro2a cells expressing
apoE4(1–272) and apoE4(1–299) (Fig. 4). Although the
precise mechanism underlying this difference is yet
unknown, it is possible that the truncation of residues
273–299 in apoE4 leads to the reorganization of the C-
terminal domain, with a lipid-binding region being less
organized and available for hydrophobic interaction
including Aβ [31-33].
Regarding the mitochondrial dysfunction in Alzheimer
disease, there are previous reports showing that the over-
expression of amyloid precursor protein increases the
level of Aβ in mitochondria [34], and that mitochondrial
complex III and IV activities are decreased in Tg2576
mouse brains [34]. In addition, the complex IV activity
was shown to decrease in the brain of AD patients [35-39].
Moreover, it has been shown that the apoE(1–272) frag-
ment is generated at a greater level from apoE4 than
apoE3, and the overexpression of apoE isoform-depend-
ently affects mitochondrial function [27]. These lines of
evidence together with our present study suggest that the
greater level of apoE4(1–272) fragment generated from
apoE4 may be associated with Aβ that is transported to
mitochondria and binds to UQCRC2 cytochrome C1 and
COX IV 1, and causes mitochondrial dysfunction.
Complexes III and IV are related to ATP synthesis and the
maintenance of mitochondrial membrane potential,
which are critical for cell survival. Thus, we examined the
Effects of overexpression of apoE4(1–272) and apoE4(1–299)  on ATP synthase activity and mitochondrial membrane  potential Figure 6
Effects of overexpression of apoE4(1–272) and 
apoE4(1–299) on ATP synthase activity and mito-
chondrial membrane potential. The ATP synthase activ-
ity in Neuro2a cells transfected with the ApoE4(1–272) and 
ApoE4(1–299) plasmids were determined (A) as described in 
the Methods. The data are the mean ± SEM of three experi-
ments. (B) Flow cytometry plots were used to determine the 
ratio of cells having normal and low mitochondrial membrane 
potentials, which were demonstrated by staining with the JC-
1 dye. The distribution of the cells sorted by FACS was ana-
lyzed, and the ratios of the number of cells showing normal 
membrane potential (C) and low membrane potential (D) to 
total cell number were calculated.
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effect of the transient expressions of apoE4(1–272) and
apoE4(1–299) on ATP synthesis and membrane potential
in Neuro2a cells. Unexpectedly, there was no difference
between apoE4(1–272)- and apoE4(1–299)-transfected
cells in terms of the levels of ATP synthesis or membrane
potential (Fig. 6). However, when we tried to generate the
Neuro2a cells, in which apoE4(1–272) is stably expressed,
all the cells were dead within 2 weeks after the transfec-
tion, whereas apoE4(1–299)-expressing cells remained
alive. These results suggest that apoE4(1–272) may have
neurotoxicity as previously reported [29], although the
level of toxicity is low. This issue remains to be addressed
in further studies.
One may consider that apoE is synthesized as a secretory
protein; however, how apoE enters the cytosol remains
unclear and controversial. Previous studies have shown
that apoE escapes the secretory or endosomal internaliza-
tion pathway, and enters the cytosol of neuronal cells
[25,29,40] and non-neuronal cells [41], whereas another
study has failed to show this [42]. Therefore, the physio-
logical relevance of the three mitochondrial proteins that
we have identified in this study, which are associated with
apoE, remains to be confirmed under physiological con-
ditions.
It is well known that apoE4 is a strong risk factor for AD
development, and the regulation of apoE4 function may
be a therapeutic target for AD. Our findings indicate that
if we could modulate the generation of apoE4(1–272)
and/or modulate its translocation to mitochondria, the
apoE4-associated induction of neurodegeneration could
be prevented or attenuated. Because it has been shown
that the C-terminus of the apoE-cleaving enzyme is a neu-
ron-specific, chymotrypsin-like serine protease [25-27],
the characterization and modulation of this enzyme activ-
ity would be a therapeutic target for AD.
Conclusion
We identified intracellular apoE-binding molecules and
determined their functions in modulating mitochondria
function. The ApoE-binding molecules we found are ubi-
quinol cytochrome c reductase core protein 2 (UQCRC2),
cytochrome C1, and cytochrome c oxidase subunit 4 iso-
form 1 (COX IV 1). The UQCRC2 and cytochrome C1 are
components of mitochondrial respiratory complex III,
and COX IV 1 is a component of complex IV. Interest-
ingly, these proteins associated with apoE4(1–272) more
strongly than intact apoE4 (1–299). When apoE4(1–272)
expression level increased in Neuro2a cells, the enzymatic
activities of mitochondrial respiratory complexes III and
IV were significantly lower than those in Neuro-2a cells
expressing apoE4(1–299). These results suggest that the
C-terminal-truncated fragment of apoE4(1–272) bind to
mitochondrial complexes and affects their activities.
Methods
Preparation of mouse brain membrane extracts and 
cytosolic fraction
Brains obtained from C57BL6 male mice were homoge-
nized with a homogenizing buffer (10 mM Tris-HCl, pH
7.4 1 mM EDTA 0.25 M sucrose), and the homogenate
was centrifuged at 1,000 g for 10 min at 4°C. The super-
natant was recentrifuged at 10,000 g for 20 min at 4°C,
and the resulting precipitate was suspended in a homoge-
nizing buffer. The supernatant was recentrifuged at
100,000 g for 1 min at 4°C, and the resulting precipitate
was suspended in a homogenizing buffer. The superna-
tant was used as the cytosolic fraction. The proteins in the
10,000 g and 100,000 g pellet fraction were extracted with
homogenizing buffer containing 1 M KCl. The resulting
pellet was solubilized with 2% Triton X-100 for 1 h at 4°C
and then centrifuged at 100,000 g  of 1 h at 4°C. The
supernatants were used as 10,000 g or 100,000 g mem-
brane extracts.
FLAG fusion proteins
Recombinant FLAG-apoE4 fusion proteins encoding WT
(1–299) or C-terminal truncated apoE4 (1–272) were pre-
pared and purified as follows. PCR products encoding
apoE4 (1–272) and apoE4 (1–299) were subcloned into
pFLAG-MAC expression vector (Sigma). These plasmids
were transformed into the BL21 strain of Escherichia coli
and induced with isopropyl-1-thio-b-D-galactopyranoside
to produce FLAG fusion proteins. The bacteria were sus-
pended in PBS, and vigorous sonication was performed
before centrifugation at 10,000 g for 20 min. The resulting
supernatants were applied to anti-FLAG M2-agarose affin-
ity resin column (Sigma) and then eluted with an elution
buffer (TBS containing 100 μg/ml FLAG peptide (Sigma)).
Purified FLAG fusion proteins were dialyzed against TBS.
FLAG-ApoE4 affinity chromatography and LC-MS/MS 
analysis
Recombinant FLAG-apoE4(1–299) or FLAG-apoE4(1–
272) fusion protein coupled to anti-FLAG M2-agarose
affinity resin was used to identify affinity-purified apoE4-
binding proteins. The fractionated mouse brain samples
were applied to the FLAG-apoE4(1–299)- and FLAG-
apoE4(1–272)-anti-FLAG M2-agarose affinity resin col-
umn. The proteins bound to the resin column were then
eluted with the elution buffer. The eluted proteins were
dialyzed against the dialysis buffer, concentrated, and
subjected to SDS-PAGE. The gels were stained with Silver-
Quest Silver Staining kit (Invitrogen). The proteins specif-
ically associated with apoEs demonstrated as silver-Molecular Neurodegeneration 2009, 4:35 http://www.molecularneurodegeneration.com/content/4/1/35
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stained bands were cut out, digested with trypsin, and
subjected to LC-MS/MS analysis.
LC-MS/MS analysis
The proteins in the silver-stained bands were reduced with
10 mM dithiothreitol at room temperature for 2 h and
alkylated with 40 mM iodoacetamide in the dark at room
temperature for 30 min. Each sample was digested with
trypsin (4 μg/ml; Trypsin Gold, Promega) in 40 mM
NH4HCO3/10%ACN at 37°C overnight. The extracted
peptides were then separated via nano liquid chromatog-
raphy (LC) (Paradigm MS4, Michrom BioResources, Inc.,
Auburn, CA) using a Magic C18 column (0.2 × 50 mm;
Michrom BioResources, Inc.; Auburn, CA). The LC eluent
was analyzed using an LCQ Advantage MAX mass spec-
trometer (Thermo Fisher Scientific) equipped with an ion-
spray source. All MS/MS spectra were searched by
SEQUEST algorithm from BioWorks software (Thermo
Fisher Scientific).
Cells
Neuro2a cells were grown in DMEM medium, supple-
mented with 10% FBS, 50 units/ml penicillin, 50 mg/ml
streptomycin, and 2 mM glutamine at 37°C in a humidi-
fied 5% CO2 95% air incubator.
Transfection of plasmids into cells and co-
immunopricipitation
PCR products encoding apoE4 (1–272) and apoE4 (1–
299) were subcloned into pFLAG-CMV-2 expression vec-
tor (Sigma). Neuro2a cells were co-transfected with FLAG-
apoE4 (1–272 or 1–299) plasmids and mammalian
expression plasmids coding the candidate of apoE4 asso-
ciating proteins (Toyobo, Japan) using Lipofectamine
2000 (Invitrogen, CA, USA). As necessary, mammalian
expression plasmids coding the candidate apoE4-associ-
ated proteins were fused with HA-tag of their C-terminus
using KOD-PLUS Mutagenesis Kit (Toyobo). The plas-
mids were transfected to Neuro2a cells as follows.
Neuro2a cells were plated on a 6-cm plate at a cell density
of 1.5 × 106 and cultured in the culture medium described
above. The next day, the ells were transfected with the
plasmid employing Lipofectamine 2000 reagent. On cul-
ture day 3, the cells were lysed with 500 μl of Triton X-100
solubilization buffer (10 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 1 mM EDTA, 10 mg/ml leupeptin, 1 mM PMSF,
0.5% Triton X-100). The cell lysate was incubated with
anti-FLAG M2-agarose affinity resin. After an overnight
incubation at 4°C, the beads were washed three times
with Triton X-100 solubilization buffer and then eluted
with the elution buffer (PBS containing FLAG peptide at a
concentration of 100 μg/ml). The immunoprecipitates
were then analyzed by western blotting with anti-HA
monoclonal antibody (Sigma), anti-UQCRC2 mono-
clonal antibody (Abcam), and anti-COX IV 1 monoclonal
antibody (Cell Signaling).
Enzymatic analysis of complexes III and IV
Mitochondria isolated from homogenates of Neuro2a
cells transfected with ApoE4 (1–299 or 1–272) were used
for enzymatic analysis.
(a) Complex III (Ubiquinol cytochrome c reductase)
The oxidation of ubiquinol2 by complex III was deter-
mined using cytochrome c (III) as an electron acceptor.
The assay was carried out in an assay medium (25 mM
potassium phosphate buffer (pH 8.0), 1 mM EDTA, 1 mM
KCN, 3 mM Na3N) supplemented with 20 μM cyto-
chrome c (III), and 20 μM ubiquinol2. The reaction was
started with 5 μg of mitochondrial protein and the
enzyme activity was measured at 550 nm. The activity of
complex III is estimated to be the difference in the reduc-
tion of cytochrome c with and without 10 μg/ml antimy-
cin A and 10 μg/ml myxothiazol.
(b) Complex IV (Cytochrome c Oxidase)
The enzyme activity of cytochrome c oxidase (complex IV)
was determined using Mitochondria Activity Assay kit
(BioChain Institute, U.S.A.) and performed following the
manufacture's procedure. Complex IV activity was meas-
ured as the oxidation of ferrocytochrome c by cytochrome
c oxidase at 550 nm. Complex IV activity is expressed as
the difference in the oxidation of ferrocytochrome C with
or without KCN and Na3N as complex IV inhibitor.
ATP synthase activity assay
Neuro2a cells transfected with apoE4(1–272) and
apoE4(1–299) plasmids were harvested and homoge-
nized with a homogenizing buffer (10 mM Tris-HCl, pH
7.4, 1 mM EDTA, 0.25 M sucrose), and the homogenate
was centrifuged at 1,000 g for 10 min at 4°C. The resulting
supernatant was further centrifuged at 10,000 × g for 20
min at 4°C, and the resulting pellet (ppt) fractions were
obtained. The ppt fractions were resuspended in 100 μl of
assay buffer (1 mM ADP and 5 mM sodium succinate)
and incubated for 5 min at 37°C. 100 mM Tris-HCl buffer
(pH 7.6) containing 4 mM EDTA was added and the frac-
tions were further incubated for 2 min at 100°C. Then the
fractions were plated on ice and ATP level in each fraction
was determined using an ATP bioluminescence assay kit
CLS II (Roche Diagnosis GmbH, Mannheim, Germany).
Analysis of mitochondrial membrane potential (mt )
ApoE4(1–272 or 1–299)-transfected Neuro2a cells were
stained with 2 μM JC-1 (Molecular Probes, Eugene, OR) at
37°C for 20 min. Then, the cells were analyzed using a
flow cytometer FACSCalibur (Becton Dickinson, Franklin
Lakes, NJ) with FlowJo software (Tree Star Inc., Ashland,
OR).
Statistical analysis
StatView computer software (Windows) was used for sta-
tistical analysis. Statistical significance of differencesMolecular Neurodegeneration 2009, 4:35 http://www.molecularneurodegeneration.com/content/4/1/35
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between samples was evaluated by multiple pairwise com-
parisons among the sets of data using ANOVA and the
Bonferoni t-test.
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